Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dorzagliatin/insulin - Hua Medicine

Drug Profile

Dorzagliatin/insulin - Hua Medicine

Alternative Names: HMS-6789

Latest Information Update: 28 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hua Medicine
  • Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
  • Mechanism of Action Glucokinase stimulants; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 28 Sep 2022 Dorzagliatin/insulin - Hua Medicine is available for licensing as of 01 Aug 2022. https://www.huamedicine.com/Public/Uploads/uploadfile2/files/20220826/20220826135005_63085f0dde779.pdf
  • 30 Jun 2021 Preclinical trials in Type 1 diabetes mellitus in China, prior to June 2021 (Hua Medicine pipeline, September 2022)
  • 30 Jun 2021 Preclinical trials in Type 2 diabetes mellitus in China, prior to June 2021 (Hua Medicine pipeline, September 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top